Posted 3/26/2024, 3:28:22 PM
Viking Therapeutics Shares Rise on Positive Early Data for Oral Obesity Drug
- Viking Therapeutics stock up 25% after positive phase 1 results for oral obesity drug VK2735
- Patients saw up to 3.3% weight loss after 28 days on oral VK2735, less than injectable but early results
- Safety and tolerability of drug were good, with only mild or moderate side effects
- Viking plans to advance oral VK2735 to phase 2 studies and move injectable formulation into late-stage testing
- Viking's robust pipeline including VK2809 NASH treatment expected to support continued share gains
